BIOJECT RECEIVES MEDICAL DEVICE REGISTRATION IN THE PHILIPPINES
Tigard, OR – December 18, 2014 – Bioject Medical Technologies Inc. (OTC Pink: BJCT), a leading developer and manufacturer of needle-free injection therapy systems, announced that its distributor in the Republic of the Philippines, Elba Pharmaceuticals has received a Certificate of Product Registration for Bioject’s ZetaJet™ injector system. Elba Pharmaceuticals is now able to market the full line of Bioject’s commercial products in the Philippines.
Stated Mark Logomasini, Bioject’s President and CEO, “We appreciate the efforts of Dr. Baura and Elba Pharmaceuticals to make the ZetaJet available to this growing customer base. It is another example of our continuing progress in expansion in international markets.”
Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is an innovative developer and manufacturer of needle-free injection therapy systems (NFITS). NFITS works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. Bioject is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies, as well as research, global health and government organizations.
Bioject (OTC Pink: BJCT) trades on the OTC Pink tier of the OTC market. Investors can find Real-Time quotes and market information for the Company on www.otcmarkets.com.
For more information about Bioject, visit www.bioject.com
